SI2076260T1 - Spojine N-metilaminometil izoindola in sestavki, ki jih vsebujejo in postopki uporabe le-teh - Google Patents
Spojine N-metilaminometil izoindola in sestavki, ki jih vsebujejo in postopki uporabe le-tehInfo
- Publication number
- SI2076260T1 SI2076260T1 SI200730569T SI200730569T SI2076260T1 SI 2076260 T1 SI2076260 T1 SI 2076260T1 SI 200730569 T SI200730569 T SI 200730569T SI 200730569 T SI200730569 T SI 200730569T SI 2076260 T1 SI2076260 T1 SI 2076260T1
- Authority
- SI
- Slovenia
- Prior art keywords
- compositions
- methods
- same
- isoindole compounds
- methylaminomethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84522706P | 2006-09-15 | 2006-09-15 | |
PCT/US2007/020201 WO2008033567A1 (en) | 2006-09-15 | 2007-09-14 | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same |
EP07838415A EP2076260B1 (en) | 2006-09-15 | 2007-09-14 | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2076260T1 true SI2076260T1 (sl) | 2011-05-31 |
Family
ID=38983295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200730569T SI2076260T1 (sl) | 2006-09-15 | 2007-09-14 | Spojine N-metilaminometil izoindola in sestavki, ki jih vsebujejo in postopki uporabe le-teh |
Country Status (30)
Country | Link |
---|---|
US (2) | US8648096B2 (sl) |
EP (1) | EP2076260B1 (sl) |
JP (1) | JP5567339B2 (sl) |
KR (1) | KR20090050107A (sl) |
CN (2) | CN103382197A (sl) |
AR (1) | AR062875A1 (sl) |
AT (1) | ATE502634T1 (sl) |
CA (1) | CA2663376C (sl) |
CL (1) | CL2007002670A1 (sl) |
CO (1) | CO6180446A2 (sl) |
CR (1) | CR10696A (sl) |
CY (1) | CY1112558T1 (sl) |
DE (1) | DE602007013436D1 (sl) |
DK (1) | DK2076260T3 (sl) |
ES (1) | ES2361584T3 (sl) |
HR (1) | HRP20110261T1 (sl) |
IL (1) | IL197566A0 (sl) |
MX (1) | MX2009002666A (sl) |
NI (1) | NI200900031A (sl) |
NZ (1) | NZ575689A (sl) |
PE (1) | PE20080832A1 (sl) |
PL (1) | PL2076260T3 (sl) |
PT (1) | PT2076260E (sl) |
RS (1) | RS51725B (sl) |
RU (1) | RU2009114159A (sl) |
SI (1) | SI2076260T1 (sl) |
TW (1) | TW200819435A (sl) |
UA (1) | UA95975C2 (sl) |
WO (1) | WO2008033567A1 (sl) |
ZA (1) | ZA200901852B (sl) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0514865A (pt) * | 2004-09-03 | 2008-06-24 | Celgene Corp | processo para preparar um composto |
CN102643267B (zh) | 2005-06-30 | 2015-09-16 | 细胞基因公司 | 4-氨基-2-(2,6-二氧哌啶-3-基)异吲哚啉-1,3-二酮化合物的制备方法 |
NZ575689A (en) * | 2006-09-15 | 2011-12-22 | Celgene Corp | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same |
US20100160368A1 (en) | 2008-08-18 | 2010-06-24 | Gregory Jefferson J | Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy |
PL2358697T3 (pl) | 2008-10-29 | 2016-04-29 | Celgene Corp | Związki izoindolinowe do zastosowania w leczeniu raka |
MX346455B (es) | 2008-12-19 | 2017-03-21 | Medicis Pharmaceutical Corp | Formulaciones de imiquimod de baja concentracion de dosis y regimenes de dosis de corta duracion para tratar queratosis actinica. |
WO2011008324A1 (en) | 2009-07-13 | 2011-01-20 | Graceway Pharmaceuticals, Llc | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
SI2536706T1 (sl) | 2010-02-11 | 2017-10-30 | Celgene Corporation | Derivati arilmetoksi izoindolina in sestavki,ki jih vsebujejo ter metode uporabe le-teh |
CA2867134C (en) | 2011-03-28 | 2019-05-07 | Sheila Dewitt | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
AU2014205043B2 (en) | 2013-01-14 | 2018-10-04 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
JP2016518336A (ja) | 2013-03-14 | 2016-06-23 | エピザイム,インコーポレイティド | Prmt1阻害剤としてのピラゾール誘導体およびその使用 |
SG11201506972PA (en) | 2013-03-14 | 2015-10-29 | Epizyme Inc | Arginine methyltransferase inhibitors and uses thereof |
US20160031839A1 (en) | 2013-03-14 | 2016-02-04 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
US9120757B2 (en) | 2013-03-14 | 2015-09-01 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
WO2014153235A2 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
EP2970181B1 (en) | 2013-03-14 | 2017-06-07 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
EP2970135B1 (en) | 2013-03-14 | 2018-07-18 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
WO2014153214A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyl transferase inhibtors and uses thereof |
US9776972B2 (en) | 2013-03-14 | 2017-10-03 | Epizyme Inc. | Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof |
US9290475B2 (en) | 2013-03-14 | 2016-03-22 | Deuterx, Llc | 3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same |
EP2970133B1 (en) | 2013-03-14 | 2018-10-24 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
EP2986318A1 (en) | 2013-04-17 | 2016-02-24 | Signal Pharmaceuticals, LLC | Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer |
UA117141C2 (uk) | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
US10316030B2 (en) | 2014-08-07 | 2019-06-11 | Calithera Biosciences, Inc. | Crystal forms of glutaminase inhibitors |
US10017492B2 (en) * | 2014-10-30 | 2018-07-10 | Kangpu Biopharmaceuticals, Ltd. | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof |
US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
WO2017040376A1 (en) * | 2015-08-31 | 2017-03-09 | The University Of Toledo | Potent phthalate inhibitors of aspartate n-acetyltransferase and selective aspartate pathway inhibitors |
BR112018011851A2 (pt) | 2015-12-15 | 2018-12-04 | Astrazeneca Ab | compostos de isoindol |
WO2017176958A1 (en) * | 2016-04-06 | 2017-10-12 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
EP3454856A4 (en) | 2016-05-10 | 2019-12-25 | C4 Therapeutics, Inc. | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
CA3041840A1 (en) | 2016-10-28 | 2018-05-03 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating ezh2-mediated cancer |
US11541051B2 (en) | 2016-12-08 | 2023-01-03 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating CDK4/6-mediated cancer |
JP2020524660A (ja) | 2017-06-14 | 2020-08-20 | アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag | Ror−ガンマモジュレーターとして有用な2,3−ジヒドロイソインドール−1−カルボキサミド |
WO2018237026A1 (en) | 2017-06-20 | 2018-12-27 | C4 Therapeutics, Inc. | N / O-LINKED DEGRONS AND DEGRONIMERS FOR DEGRADATION OF PROTEINS |
WO2019043208A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROQUINOLINONES |
CN111278815B (zh) | 2017-09-04 | 2024-03-08 | C4医药公司 | 戊二酰亚胺 |
CN111315735B (zh) | 2017-09-04 | 2024-03-08 | C4医药公司 | 二氢苯并咪唑酮 |
EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
CN112154146A (zh) * | 2018-03-06 | 2020-12-29 | 西奈山伊坎医学院 | 丝氨酸苏氨酸激酶(akt)降解/破坏化合物和使用方法 |
EP3773576A4 (en) | 2018-03-26 | 2021-12-29 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
ES2959622T3 (es) | 2018-04-23 | 2024-02-27 | Celgene Corp | Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para tratar el linfoma |
EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
JP2022527216A (ja) | 2019-04-12 | 2022-05-31 | シー4 セラピューティクス, インコーポレイテッド | Ikaros及びAiolosの三環式分解誘導薬 |
KR20220103949A (ko) * | 2019-10-21 | 2022-07-25 | 셀진 코포레이션 | 혈액암을 치료하는 방법 및 2-(2,6-디옥소피페리딘-3-일)-4-((2-플루오로-4-((3-모르폴리노아제티딘-1-일)메틸)벤질)아미노)이소인돌린-1,3-디온에 대한 동반 바이오마커의 용도 |
CN115919870A (zh) | 2019-10-21 | 2023-04-07 | 新基公司 | 使用化合物治疗慢性淋巴细胞白血病的方法 |
CN110746400B (zh) * | 2019-11-07 | 2021-12-17 | 郑州大学 | 一种靶向雄激素受体的荧光探针及其制备方法 |
JP2024504932A (ja) | 2021-01-13 | 2024-02-02 | モンテ ローザ セラピューティクス, インコーポレイテッド | イソインドリノン化合物 |
CN115504963A (zh) * | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | 一种c-Myc蛋白降解剂 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
CN100390163C (zh) * | 1998-03-16 | 2008-05-28 | 赛尔金有限公司 | 2-(2,6-二氧哌啶-3-基)-异二氢吲哚衍生物、其制法及其作为炎性细胞因子抑制剂的用途 |
US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
WO2004054977A1 (en) * | 2002-12-13 | 2004-07-01 | Cytopia Pty Ltd | Nicotinamide-based kinase inhibitors |
US20050143344A1 (en) * | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
CN102643267B (zh) * | 2005-06-30 | 2015-09-16 | 细胞基因公司 | 4-氨基-2-(2,6-二氧哌啶-3-基)异吲哚啉-1,3-二酮化合物的制备方法 |
NZ575689A (en) * | 2006-09-15 | 2011-12-22 | Celgene Corp | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same |
-
2007
- 2007-09-14 NZ NZ575689A patent/NZ575689A/en not_active IP Right Cessation
- 2007-09-14 CN CN2013102182141A patent/CN103382197A/zh active Pending
- 2007-09-14 EP EP07838415A patent/EP2076260B1/en active Active
- 2007-09-14 US US11/901,291 patent/US8648096B2/en active Active
- 2007-09-14 JP JP2009528337A patent/JP5567339B2/ja active Active
- 2007-09-14 CN CNA2007800424312A patent/CN101534820A/zh active Pending
- 2007-09-14 UA UAA200903664A patent/UA95975C2/ru unknown
- 2007-09-14 AT AT07838415T patent/ATE502634T1/de active
- 2007-09-14 ES ES07838415T patent/ES2361584T3/es active Active
- 2007-09-14 PL PL07838415T patent/PL2076260T3/pl unknown
- 2007-09-14 RS RS20110258A patent/RS51725B/en unknown
- 2007-09-14 KR KR1020097006986A patent/KR20090050107A/ko not_active Application Discontinuation
- 2007-09-14 RU RU2009114159/15A patent/RU2009114159A/ru not_active Application Discontinuation
- 2007-09-14 SI SI200730569T patent/SI2076260T1/sl unknown
- 2007-09-14 PT PT07838415T patent/PT2076260E/pt unknown
- 2007-09-14 WO PCT/US2007/020201 patent/WO2008033567A1/en active Application Filing
- 2007-09-14 CL CL200702670A patent/CL2007002670A1/es unknown
- 2007-09-14 DE DE602007013436T patent/DE602007013436D1/de active Active
- 2007-09-14 ZA ZA200901852A patent/ZA200901852B/xx unknown
- 2007-09-14 TW TW096134612A patent/TW200819435A/zh unknown
- 2007-09-14 DK DK07838415.3T patent/DK2076260T3/da active
- 2007-09-14 CA CA2663376A patent/CA2663376C/en active Active
- 2007-09-14 MX MX2009002666A patent/MX2009002666A/es active IP Right Grant
- 2007-09-17 AR ARP070104112A patent/AR062875A1/es unknown
- 2007-09-17 PE PE2007001253A patent/PE20080832A1/es not_active Application Discontinuation
-
2009
- 2009-03-12 IL IL197566A patent/IL197566A0/en unknown
- 2009-03-13 NI NI200900031A patent/NI200900031A/es unknown
- 2009-03-30 CR CR10696A patent/CR10696A/es not_active Application Discontinuation
- 2009-04-03 CO CO09034806A patent/CO6180446A2/es not_active Application Discontinuation
-
2011
- 2011-04-12 HR HR20110261T patent/HRP20110261T1/hr unknown
- 2011-05-20 CY CY20111100500T patent/CY1112558T1/el unknown
-
2013
- 2013-12-30 US US14/144,292 patent/US20140113935A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL197566A0 (en) | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same | |
ZA200802490B (en) | Isoindole-imide compounds and compositions comprising and methods of using the same | |
PT2101766T (pt) | Composições e métodos de utilização de (r)-pramipexole | |
EP1883389A4 (en) | LOW IRRITANT COMPOSITIONS AND METHODS OF MAKING SAME | |
PL2335782T3 (pl) | Zastosowanie kompozycji zawierającej HFCO-1233zd | |
EP1895838A4 (en) | COMPOSITIONS AND METHODS | |
IL181543A0 (en) | Dendrimer based compositions and methods of using the same | |
EP2057284A4 (en) | COMPOSITIONS AND METHODS FOR MODULATION OF JNK PROTEINS | |
IL180907A0 (en) | Risedronate compositions and their methods of use | |
ZA200808431B (en) | Fungicidal compositions and methods of using the same | |
IL191072A0 (en) | Therapeutic compositions and methods | |
EP2067796A4 (en) | POLYMERIZABLE COMPOUND AND POLYMERIZABLE COMPOSITION | |
PL2101766T3 (pl) | Kompozycje i sposoby stosowania (R)-pramipeksolu | |
EP2101731A4 (en) | PROCESSES AND COMPOSITIONS WITH END OXIFES | |
PL2069467T3 (pl) | Kompozycje wydzielające i sposoby stosowania | |
EP2104554A4 (en) | particle compositions | |
EP2088865A4 (en) | METHODS AND COMPOSITIONS AROUND GUGGULPHOSPHOLIPIDS | |
GB0617171D0 (en) | Novel compositions and methods | |
HK1109576A1 (en) | Aequorin-containing compositions and methods of using same | |
EP2098544A4 (en) | POLYMERIZABLE COMPOUNDS AND POLYMERIZABLE COMPOSITIONS | |
IL186606A0 (en) | Compositions and uses of amooranin compounds | |
GB0412584D0 (en) | Composition of matter | |
GB0501348D0 (en) | Compositions and methods | |
EP2046109A4 (en) | PHOTOSYNTHETIC ORGANISMS, COMPOSITIONS AND METHODS FOR GENERATING THESE ORGANISMS | |
IL195845A0 (en) | Methods of making and using rubidium-81-containing compositions |